stock.name

Ionis Pharmaceuticals Inc

IONS

Market Cap$6B
Close$

Compare to Similar Companies

P/E RatioDividendsReturn on EquityPrice-to-SalesDebt-to-Equity
Ionis Pharmaceuticals IncIonis Pharmaceuticals Inc-15.60%-130%8.24.3
$55.50

Target Price by Analysts

36% upsideIonis Pharmaceuticals Target Price DetailsTarget Price
$-21.89

Current Fair Value

153.6% downside

Overvalued by 153.6% based on the discounted cash flow analysis.

Share Statistics

Market cap$6.00 Billion
Enterprise Value$5.07 Billion
Dividend Yield$0.0 (0.0%)
Earnings per Share$-2.67
Beta0.0
Outstanding Shares145,965,374
Avg 30 Day Volume1,160,616

Return

Return on Equity-
Return on Assets-
Return on Invested Capital-

Valuation & Multiples

P/E Ratio-15.6
PEG-104.94
Price to Sales8.16
Price to Book Ratio20.41
Enterprise Value to Revenue6.53
Enterprise Value to EBIT-13.03
Enterprise Value to Net Income-14
Total Debt to Enterprise0.25
Debt to Equity4.3

Revenue Sources

No data

Insider Trades

ESG Score

No data

About Ionis Pharmaceuticals Inc

817 employees
CEO: Brett Monia

Ionis Pharmaceuticals is a biotechnology company based in Carlsbad, California that specializes in discovering and developing RNA-targeted therapeutics. The company has 3 commercially approved medicines: Spinraza , Tegsedi , and WAYLIVRA...